1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Geron Sees Blockbuster Opportunity For Imetelstat, Eyeing Broader Market Than Reblozyl’s

 
• By Alaric DeArment

The company reported positive results from its study in lower-risk myelodysplastic syndrome, where it forecasts a market potentially exceeding 30,000 in US and major European markets and generating up to $1.2bn in sales.

Geron announced Phase III results for imetelstat in lower-risk myelodysplastic syndrome • Source: Shutterstock

Geron Corporation anticipates that imetelstat sales could potentially exceed $1bn and sees a strong competitive positioning relative to Bristol Myers Squibb Company’s Reblozyl (luspatercept-aamt) in lower-risk myelodysplastic syndrome (MDS), assuming positive Phase III data lead to US and European regulatory approvals.

The company announced on 4 January positive topline results from the IMerge Phase III trial that compared imetelstat, a telomerase inhibitor, against placebo and showed solid improvement in the percentage of patients meeting the primary endpoint of transfusion independence, both

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

End Is Nigh For 4SC After EMA’s No For Kinselby

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

More from Therapy Areas

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.